tert-Butyl piperazine-1-carboxylate → tert-Butyl 4-(isoquinolin-5-yl)piperazine-1-carboxylate
반응식
[CH:1]1[C:10]2[C:5](=[C:6](OS(C(F)(F)F)(=O)=O)[CH:7]=[CH:8][CH:9]=2)[CH:4]=[CH:3][N:2]=1.[C:19]([N:26]1[CH2:31][CH2:30][NH:29][CH2:28][CH2:27]1)([O:21][C:22]([CH3:25])([CH3:24])[CH3:23])=[O:20]>>[C:22]([O:21][C:19]([N:26]1[CH2:31][CH2:30][N:29]([C:6]2[CH:7]=[CH:8][CH:9]=[C:10]3[C:5]=2[CH:4]=[CH:3][N:2]=[CH:1]3)[CH2:28][CH2:27]1)=[O:20])([CH3:25])([CH3:23])[CH3:24]참가 물질
3
실험 절차
The product from step (a) above (209 mg, 0.75 mmol) and 1-BOC-piperazine (210 mg, 1.1 mmol, Aldrich) was reacted under the conditions of Example 132b to give the title compound as yellow amorphous solid, which was used for the next step. MS (ESI, pos. ion) m/z: 314 (M+1)
출처 및 근거
- ORD 기록
- ord-e0f8aa673b214877826c5d3678b9d08d
- 출처 데이터셋
- uspto-grants-2009_09
- 특허 번호
- US07582761B2
반응 노트
불러오는 중…